July 23 (Reuters) - Biopharmaceutical firm Telix Pharmaceuticals (TLX) said on Monday it has launched an offering of A$600 million ($397.5 million) of convertible notes due 2029, in a bid to fund key clinical development programs across its theranostics portfolio.
($1 = 1.5094 Australian dollars)
News: TLX Australia's Telix Pharmaceuticals launches $397.5 mln convertible bonds offering
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.08 |
Change
-0.105(0.55%) |
Mkt cap ! $6.383B | |||
| Open | High | Low | Value | Volume |
| $18.93 | $19.37 | $18.75 | $20.46M | 1.076M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3 | $19.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.08 | 1003 | 12 |
View Market Depth
| Last trade - 12.58pm 26/08/2024 (20 minute delay) ? |
| TLX (ASX) Chart |